



# APASL 2019 MANILA

20 to 24 February  
Philippine International  
Convention Center  
(PICC)



**Preliminary Program**

# Program at a Glance

20 February, **Wednesday**

7:00 AM

Registration

---

8:00 AM to 5:00 PM

**APASL-AASLD Research Methodology  
Workshop**

*Research Basics and Intricacies: From  
Conception to Completion*

---

8:30 AM to 5:30 PM

**Liver Transplant Symposium**

*Optimizing Outcomes in Liver Transplantation*

---

# Program at a Glance

21 February, **Thursday**

7:00 AM

Registration

---

8:30 AM to 5:20 PM

**Postgraduate Course**

*Current Approaches to Common Liver Problems*

---

8:30 AM to 4:00 PM

**Basic Science Course**

*NAFLD: From Basics to Clinics*

---

9:00 AM to 5:30 PM

**APASL-CEVHAP Public Health Day**

*Towards Elimination of Viral Hepatitis by 2030: From Street to Clinic*

---

# Program at a Glance

22 February, **Friday**

7:00 AM	Registration
8:15 AM to 9:45 AM	<b>Parallel Symposia I</b>
10:00 AM to 11:00 AM	<b>Opening Ceremonies</b>
11:00 AM to 11:30 AM	<b>Presidential Lecture</b>
1:00 PM to 2:30 PM	<b>Plenary Session</b>
2:30 PM to 4:00 PM	<b>Parallel Symposia II</b>
2:30 PM to 5:50 PM	<b>APASL-AASLD Symposium</b> <i>Hepatocellular Carcinoma</i>

# Program at a Glance

22 February, **Friday**

---

2:30 PM to 4:00 PM

**State of the Art Lectures**

*State of the Art Lecture I*

*State of the Art Lecture II*

*State of the Art Lecture III*

---

2:30 PM to 4:00 PM

**Oral Research Session I**

---

4:20 PM to 5:50 PM

**Parallel Symposia III**

---

4:20 PM to 5:20 PM

**State of the Art Lectures**

*State of the Art Lecture IV*

*State of the Art Lecture V*

---

4:20 PM to 5:50 PM

**Oral Research Session II**

---

# Program at a Glance

23 February, **Saturday**

7:00 AM

Registration

---

8:00 AM to 9:30 AM

**Parallel Symposia IV**

---

8:30 AM to 10:00 AM

**Parallel Symposia V**

---

9:30 AM to 10:00 AM

**State of the Art Lectures**

*State of the Art Lecture VI*

*State of the Art Lecture VII*

*State of the Art Lecture VIII*

---

10:20 AM to 11:50 AM

**Plenary Session**

---

1:30 PM to 2:00 PM

**State of the Art Lectures**

*State of the Art Lecture IX*

*State of the Art Lecture X*

---

# Program at a Glance

23 February, **Saturday**

---

2:00 PM to 5:20 PM	<b>APASL-EASL Symposium</b> <i>Alcoholic Liver Disease</i>
2:00 PM to 3:30 PM	<b>Parallel Symposia VI</b>
2:00 PM to 2:30 PM	<b>State of the Art Lectures</b> <i>State of the Art Lecture XI</i>
3:00 PM to 3:30 PM	<b>State of the Art Lectures</b> <i>State of the Art Lecture XII</i>
2:00 PM to 3:30 PM	<b>Oral Research Session V</b>
3:50 PM to 5:20 PM	<b>Parallel Symposia VII</b>
3:50 PM to 5:20 PM	<b>Oral Research Session VI</b>

---

# Program at a Glance

24 February, **Sunday**

8:30 AM to 10:00 AM	<b>Parallel Symposia VIII</b>
8:30 AM to 9:30 AM	<b>APASL Business Meeting</b>
8:30 AM to 10:00 AM	<b>APASL-GLAD Symposium</b>
8:30 AM to 11:50 AM	<b>APASL-AARC Symposium</b>
8:30 AM to 11:50 AM	<b>NAFLD in the Asia-Pacific Region</b>
10:20 AM to 11:50 AM	<b>Parallel Symposia IX</b>
10:20 AM to 11:50 AM	<b>Editor's Pick</b>
10:20 AM to 11:50 AM	<b>Parallel Symposia X</b>
1:30 PM to 3:00 PM	<b>Wrap-up Sessions</b> <i>Viral Hepatitis</i> <i>NAFLD</i> <i>Hepatocellular Carcinoma</i>
3:00 PM to 3:20 PM	<b>Closing Ceremonies</b>





# 20 February

## Wednesday

APASL-AASLD Research Methodology Workshop  
Liver Transplant Course



# APASL-AASLD

## Research Methodology Workshop

Course Directors: Stephen Wong (Manila), Ray Kim (Palo Alto), Anna Lok (Ann Arbor)

8:00 to 8:05 AM **Welcome Message**  
*Diana Payawal, Manila*

8:05 to 8:10 AM **Introduction to the Course**  
*Stephen Wong, Manila*

### Session I: Research Design and Conduct

8:10 to 8:35 AM **Balancing Novelty with Feasibility in Research Design**  
*Ray Kim, Palo Alto*

8:35 to 9:00 AM **What is and What is not Real World Data**  
*Michael Fried, Chapel Hill*

9:00 to 9:25 AM **Creating Database, Biorepository/Microbiome Studies**  
*Jasmohan Bajaj, Richmond*

9:25 to 9:50 AM **Data Management and Analysis**  
*Grace Wong, Hong Kong*

9:50 to 10:15 AM **Secondary Data Analysis**  
*Stephen Wong, Manila*

10:15 to 10:25 AM **Discussion**  
*Moderator: Ray Kim, Palo Alto*

10:25 to 10:35 AM **Coffee Break**

10:35 to 11:00 AM **Meta Analysis**  
*Fasiha Kanwal, Dallas*

11:00 to 11:25 AM **Patient Related Outcomes**  
*Janus Ong, Manila*

### Session II: Research Writing and Publication

11:25 to 11:50 AM **Cohesion in Research Writing**  
*Anna Lok, Ann Arbor*

11:50 AM to 12:15 PM **Ethics and Integrity in Research**  
*Saeed Hamid, Karachi*

12:15 to 12:25 PM **Discussion**  
*Moderator: Stephen Wong, Manila*

12:25 to 1:25 PM **Luncheon: Academic Hepatologists' Journey—East and West**  
*Masao Omata, Tokyo*  
*Anna Lok, Ann Arbor*

1:25 to 1:50 PM **The Do's and Don'ts of Persuasive Grant Writing**  
*Jacob George, Sydney*

1:50 to 2:15 PM **Get Your Research Published! What Editors and Reviewers Look At**  
*Shiv Sarin, New Delhi*

2:15 to 2:40 PM **Effective Presentation of Research Output**  
*Patrick Kamath, Rochester*

2:40 to 2:50 PM **Discussion**  
*Moderator: Janus Ong, Manila*

2:50 to 4:50 PM **Session III: Breakout Session**

4:50 to 5:20 PM **Awarding/Closing**

# Liver Transplant Course

“Optimizing Outcomes in Liver Transplantation”

Course Directors: Vanessa De Villa (Manila), Simone Strasser (Sydney)

8:30 to 8:35 AM **Introduction**  
*Vanessa De Villa, Manila*

**Session I: Liver Transplantation in Asia**  
CHAIRS: Vanessa De Villa, Simone Strasser

8:35 to 8:55 AM **Essentials for a Liver Transplant Program in The 21st Century: A Multidisciplinary Approach**  
*Robert Gish, San Diego*

8:55 to 9:15 AM **Indications for LT in the Asia-Pacific: Are They Changing?**  
*James Fung, Hong Kong*

9:15 to 9:35 AM **How Do We Increase Deceased Donor Transplantation in the Region? Lessons from Australia**  
*Geoffrey McCaughan, Sydney*

9:35 to 9:55 AM **Expanding the Donor Pool in the Asia Pacific: Use of HBsAg and Anti-HCV Positive Donors**  
*Simone Strasser, Sydney*

9:55 to 10:15 AM **Donor Safety in Live Donor Liver Transplantation**  
*Dong-Hwan Jung, Seoul*

10:15 to 10:30 AM **Discussion/Question & Answer**

10:30 to 10:45 AM **Coffee Break**

**Session II: Care of the Patient Waiting for Liver Transplant**  
CHAIRS: Eternity Labio, Geoffrey McCaughan

10:45 to 11:05 AM **Optimization of Nutrition and Physical Status in Malnourished Patients Awaiting Liver Transplantation**  
*TBA*

11:05 to 11:25 AM **Assessment and Management of Obesity and the Metabolic Syndrome in Patients with Decompensated Cirrhosis**  
*Leon Adams, Perth*

11:25 to 11:45 AM **Prevention and Management of Kidney Injury in Patients Waiting for Liver Transplant**  
*Florence Wong, Toronto*

11:45 AM to 12:05 PM **Bridging the ALF/ACLF Patient to Transplant: From Plasmapheresis to MARS**  
*Lanjuan Li, Hangzhou*

12:05 to 12:25 PM **Assessment and Management of Tuberculosis in Liver Transplant Candidates**  
*Cybele Abad, Manila*

12:25 to 12:40 PM **Discussion/Question & Answer**

12:40 to 1:40 PM **Lunch Break**

# Liver Transplant Course

“Optimizing Outcomes in Liver Transplantation”

Course Directors: Vanessa De Villa (Manila), Simone Strasser (Sydney)

## Session III: Perioperative Issues and Care in Liver Transplant

CHAIRS: Mara Teresa Panlilio, Johnny Hong

1:40 to 2:00 PM	<b>Optimization of Outcomes in ABO Incompatible Liver Transplantation</b> <i>Hidekazu Yamamoto, Kyushu</i>
2:00 to 2:20 PM	<b>Perioperative Infection Prophylaxis and Management of Posttransplant Infections</b> <i>Jack Bruminhent, Bangkok</i>
2:20 to 2:40 PM	<b>Perioperative Immunosuppression: Personalized Protocols to Improve Patient Outcomes</b> <i>Maryam Moini, Shiraz</i>
2:40 to 3:00 PM	<b>Perioperative Challenges in the High MELD Liver Transplant Candidate</b> <i>Johnny Hong, Milwaukee</i>
3:00 to 3:20 PM	<b>Assessment and Management of Graft Dysfunction in the Early Posttransplant Period</b> <i>Lawrence Liu, Cebu</i>
3:20 to 3:35 PM	<b>Discussion/Question &amp; Answer</b>
3:35 to 3:50 PM	<b>Coffee Break</b>

## Session IV: Follow-up and Long-Term Care of the Liver Transplant Patient

CHAIRS: Mark Anthony De Lusong, Simone Strasser

3:50 to 4:10 PM	<b>The Role of Interventional Endoscopy in the Management of Post-transplant Complications</b> <i>Arthur Kaffes, Sydney</i>
4:10 to 4:30 PM	<b>Prevention and Management of Recurrent HCC Post-Transplant</b> <i>Vanessa De Villa, Manila</i>
4:30 to 4:50 PM	<b>Recurrent and De Novo NASH in the Post-transplant Period</b> <i>Arun Sanyal, Richmond</i>
4:50 to 5:10 PM	<b>Access, Equity, and Accountability in Liver Transplantation in Asia Pacific</b> <i>Sanjay Nagral, Mumbai</i>
5:10 to 5:20 PM	<b>Discussion/Question &amp; Answer</b>
5:20 to 5:30 PM	<b>Closing Remarks</b> <i>Simone Strasser, Sydney</i>



# 21 February

## Thursday

Postgraduate Course  
Basic Science Course  
APASL-CEVHAP Public Health Forum

# Postgraduate Course

“Current Approaches to Common Liver Problems”

Course Directors: Jade Jamias (Manila), Patrick Kamath (Rochester)

8:30 to 8:35 AM

## Welcome Remarks

*Diana Payawal, Manila*

8:35 to 8:40 AM

## Introduction to the Course

*Jade Jamias, Manila*

## Session I: Hepatocellular Carcinoma

CHAIRS: Jade Jamias, Kadir Dökmeci

8:40 to 9:00 AM

## The Changing Epidemiology of HCC in the Asia-Pacific Region

*Jose Sollano, Manila*

9:00 to 9:20 AM

## Liver Cancer in NAFLD: Epidemiology, Clinical Characteristics, and Outcomes of Treatment

*TBA*

9:20 to 9:40 AM

## Conundrum of Intermediate HCC

*Kwang Hyub Han, Seoul*

9:40 to 10:00 AM

## Clinical Use of Novel Biomarkers for HCC

*TBA*

10:00 to 10:20 AM

## Novel Systemic Therapies for Advanced HCC

*Chuin Hsu, Taipei*

10:20 to 10:40 AM

## Coffee Break

## Session II: NAFLD/NASH

CHAIRS: Estrellita Ruiz, Osamu Yokusuka

10:40 to 11:00 AM

## Screening for NAFLD: Who, When, and How?

*Ray Kim, Palo Alto*

11:00 to 11:20 AM

## Applications of Non-invasive Tests in NAFLD

*Vincent Wong, Hong Kong*

11:20 to 11:40 AM

## Disease Progression in NAFLD: Who are at Risk?

*Stephen Wong, Manila*

11:40 AM to 12:00 PM

## NASH Cirrhosis and Cirrhosis of Other Etiologies: Are Their Courses Different?

*Ajay Duseja, Chandigarh*

12:00 to 12:20 PM

## Practical Approach to Dietary and Lifestyle Modification in NAFLD

*Jacob George, Sydney*

12:20 to 1:30 PM

## Lunch Break

# Postgraduate Course

“Current Approaches to Common Liver Problems”

Course Directors: Jade Jamias (Manila), Patrick Kamath (Rochester)

## Session III: Viral Hepatitis

CHAIRS: Virgilio Banez, David Muljono

1:30 to 1:50 PM **E Antigen Positive Chronic Infection/Immune Tolerant CHB: Treat or Not to Treat?**

*Anna Lok, Ann Arbor*

1:50 to 2:10 PM **The Use of Novel Biomarkers in the Management for Chronic Hepatitis B: Are They Ready for Primetime?**

*Jinlin Hou, Guangzhou*

2:10 to 2:30 PM **Hepatitis C in Special Populations (CKD, Decompensated CLD, and Post-LT): a Guide on Treatment**

*Michael Fried, Chapel Hill*

2:30 to 2:50 PM **Extrahepatic Manifestations of Hepatitis C: The Role of DAAs**

*Jia-Horng Kao, Taipei*

2:50 to 3:10 PM **Hepatitis E in the Asia-Pacific Region**

*Rakesh Aggarwal, Lucknow*

3:10 to 3:30 PM **Coffee Break**

## Session IV: Liver Cirrhosis and Its Complications

CHAIRS: Erlinda Valdellon, Laurentius Lesmana

3:30 to 3:50 PM **Patient-related Outcomes in Patients with Chronic Liver Disease**

*Zobair Younossi, Fairfax*

3:50 to 4:10 PM **AKI in Cirrhosis: Recognition and Management**

*Jasmohan Bajaj, Richmond*

4:10 to 4:30 PM **Physical Conditioning and Feeding the Malnourished/Sarcopenic Cirrhotic Patient**

*Rajender Reddy, Philadelphia*

4:30 to 4:50 PM **Beta Blockers In Decompensated Cirrhotic: Friend or Foe?**

*Yogesh Chawla, Chandigarh*

4:50 to 5:10 PM **Bacterial Infections in Cirrhosis: Recognition and Practical Guidance**

*Patrick Kamath, Rochester*

5:10 to 5:20 PM **Closing Remarks**

*Patrick Kamath, Rochester*



# Basic Science Course

## “NAFLD: From Basics to Clinics”

Course Directors: Janus Ong (Manila), Mohammed Eslam (Sydney),  
Jacob George (Sydney)

8:30 to 8:40 AM

### Welcome and Introduction

*Janus Ong, Manila*

### Session I: Update on NAFLD

CHAIRS: Mohammed Eslam, Arun Sanyal

8:40 to 9:00 AM

### Novel *in vivo* Models for NAFLD

*Arun Sanyal, Richmond*

9:00 to 9:20 AM

### Three-dimensional Organoids and Liver Tissue

*Hideki Taniguchi, Yokohama*

9:20 to 9:40 AM

### Nutrition and NAFLD

*David Raubenheimer, Sydney*

9:40 to 10:00 AM

### Adipose Tissue and NAFLD

*Faidon Magkos, Copenhagen*

10:00 to 10:20 AM

### Muscle and NAFLD

*Kyung Mook Choi, Seoul*

10:20 to 10:30 AM

### Discussion/Question & Answer

10:30 to 10:50 AM

### Coffee Break

### Session II: Inflammation and Fibrosis in NAFLD

CHAIRS: Vlad Ratzui, Hideki Taniguchi

10:50 to 11:10 AM

### Mechanisms and Sources of Inflammation

*Vlad Ratzui, Paris*

11:10 to 11:30 AM

### Bioenergetics and NAFLD

*Masaaki Komatsu, Niigata*

11:30 to 11:50 AM

### Novel Serum Biomarkers Including Metabolomics-Based Biomarkers

*Henning Gronbaek, Aarhus*

11:50 AM to 12:10 PM

### Discussion/Question & Answer

12:10 to 1:40 PM

### Lunch Break

# Basic Science Course

## “NAFLD: From Basics to Clinics”

Course Directors: Janus Ong (Manila), Mohammed Eslam (Sydney),  
Jacob George (Sydney)

### Session III: Viral Hepatitis

CHAIRS: Jun Yu, Mark Febbraio

1:40 to 2:00 PM **Mechanisms of NAFLD-HCC in Non-Cirrhosis**  
*Jun Yu, Hong Kong*

2:00 to 2:20 PM **Mutational Landscape of HCC**  
*TBA*

2:20 to 2:40 PM **Gut-Liver Axis in NAFLD and HCC**  
*Detlef Schuppan, Mainz*

2:40 to 2:50 PM **Discussion/Question & Answer**

2:50 to 3:10 PM **Coffee Break**

### Session IV: Novel Therapeutic Approaches

CHAIRS: Tatsuhiro Shibata, Jacob George

3:10 to 3:30 PM **Nuclear Receptors and NAFLD**  
*TBA*

3:30 to 3:50 PM **Mechanism of Exercise Effect in NAFLD**  
*Mark Febbraio, Sydney*

3:40 to 4:10 PM **Stem Cell and Liver Diseases**  
*Shiv Sarin, New Delhi*

4:10 to 4:30 PM **HCC Immunotherapy**  
*Chen Dong, Beijing*

4:30 to 4:40 PM **Discussion**  
*Jacob George, Sydney*

4:40 to 4:50 PM **Closing Remarks**  
*Jacob George, Sydney*

# Public Health Forum

“Towards Elimination of Viral Hepatitis by 2030: From Street to Clinic”

## Introduction and Welcome

CHAIR: Rosmawati Mohamed

9:00 to 9:05 AM

### Opening and Welcome Remarks

*Diana Payawal, Manila*

9:05 to 9:20 AM

### Keynote Speech: Addressing Discrimination and its Impact on Human Rights - The Role of the Legislator

*JV Ejercito, Manila*

9:20 to 9:40 AM

### Regional Progress in Implementation at Regional Action Plans

*Po-Lin Chan, Manila*

*BB Rewari, New Delhi*

## Topic 1: Addressing Critical Barriers in Viral Hepatitis: Stigma and Discrimination

CHAIRS: Janus Ong, Naoko Ishikawa

9:40 to 9:55 AM

### Identifying and Quantifying Stigma

*Jack Wallace, Melbourne*

9:55 to 10:05 AM

### The Social Stigma of Viral Hepatitis: The Patient's Perspective

*Chris Muñoz, Manila*

10:05 to 10:15 AM

### Addressing Stigma: The Role of the Physician

*Angela Salvaña, Manila*

10:15 to 10:30 AM

### Stigma and Discrimination Towards People Living with HBV in China

*Binfeng Han, Beijing*

10:30 to 10:45 AM

### Panel/Question & Answer

10:45 to 11:00 AM

### Coffee Break

## Topic 2: From Prevention to Access to Testing and Linking Care

CHAIRS: Eternity Labio, Chris Muñoz

11:00 to 11:10 AM

### WHO Systematic Review: Good Practices for Simplified Service Delivery for Testing, Link to Care and Treatment for HCV

*Phillippa Easterbrook, Geneva*

11:10 to 11:20 AM

### Country Case Study 1 Hepatitis Advocacy in the Elimination Initiative

*Rosmawati Mohamed, Kuala Lumpur*

11:20 to 10:30 AM

### Harm Reduction in PWIDs: Philippines

*Ma Inez Feria, Manila*

11:30 to 11:40 AM

### Country Case Study 2: HCV Model Program in General Population, Punjab Province, India

*Gagandeep Grover, Punjab*

11:40 to 11:50 AM

### Public Health Case Study 3: Taiwan HCV Control Program

*Jia-Horng Kao, Taipei*

11:50 AM to 12:00 PM

### Panel/Question & Answer

# Public Health Forum

“Towards Elimination of Viral Hepatitis by 2030: From Street to Clinic”

## ADVOCACY WORKSHOP (by Invitation)

### ASIA PACIFIC HEPATITIS SUMMIT 2019: "Building the Hepatitis Advocacy Voice in Asia Pacific"

12:00 to 12:10 PM

#### **Background Overview – What’s Next After Brazil?**

*Wangsheng Li*

#### **Workshop Objectives**

*Suzanne Wait*

12:00 to 12:45 PM

#### **Exercise 1**

12:45 to 1:00 PM

#### **Working Luncheon**

1:00 to 1:45 PM

#### **Exercise 2**

1:45 to 2:00 PM

#### **Wrap-Up**

## Topic 3: Towards an Effective Cascade of Linkage to Care - Treatment and Follow-up: Innovations and Best Practices

CHAIRS: Jack Wallace, Po-lin Chan

2:00 to 2:15 PM

#### **Finding the Missing Millions: A Patient's Perspective on the Current Cascade of Care in Asia Pacific Region**

*Michael Ninberg, Seattle*

2:15 to 2:25 PM

#### **FIND - Innovation in Testing and Decentralized Service Delivery**

*Francesco Marinucci, Geneva*

2:25 to 2:35 PM

#### **Country Case Study 4: Pakistan - Treating in the Community: Addressing Challenges to Treatment Access and Monitoring**

*Saeed Hamid, Karachi*

2:35 to 2:45 PM

#### **Country Case Study 5: Mongolia - Elimination of Hepatitis as a Public Health Threat**

*Baatarbileg Yondonperelei, Mongolia*

2:45 to 2:55 PM

#### **Country Case Study 6: Cambodia - Simplified Testing Algorithm and Service Delivery Model Can Improve Access to Care**

*MSF Cambodia*

2:55 to 3:05 PM

#### **Country Case Study 7: Philippines - National Challenges Towards Elimination**

*Gerard Belimac, Manila*

3:05 to 3:30 PM

#### **Panel/Question & Answer**

3:30 to 3:45 PM

#### **Coffee Break**

# Public Health Forum

“Towards Elimination of Viral Hepatitis by 2030: From Street to Clinic”

## Hard Chat Roundtable: Where Do We Go From Here - Opportunities and Future Directions

CHAIRS: Raquel Peck and Saeed Hamid

3:45 to 3:55 PM

### **CONTEXT: What Do the Numbers Tell Us About How We're Progressing?**

*Homie Razavi, Lafayette*

### **Universal Health Care and Financing**

*Peter Cowley, Coordinator for Health Financing and Planning, WHO*

### **Financing and Initiatives in Asia**

*Wangsheng Li, President, ZeShan Foundation*

3:55 to 4:30 PM

Panel Discussion

### **Collaboration and Tech Hub**

*John Ward, Director, Viral Hepatitis Elimination Program at The Task Force for Global Health*

### **Issues Specific to Southeast Asian Region**

*Focal Point, SEARO*

### **Issues Specific to Western Pacific Region**

*Po-lin Chan, Manila*

4:30 to 4:50 PM

### **Panel/Question & Answer**

4:50 to 5:00 PM

### **Closing Remarks**

*Rino Gani, Jakarta*



# 22 February

## Friday

# Morning Parallel Symposia

## Hepatitis B I

Meeting Room 1, 8:30 to 10:00 AM

Chairs: Jen Agcaoili (Manila), George Lau (Beijing)

8:30 to 8:50 AM	<b>Treatment Endpoints in Chronic Hepatitis B Therapy</b> <i>Jinlin Hou, Guangzhou</i>
8:50 to 9:10 AM	<b>Future Therapies for Chronic Hepatitis B</b> <i>Henry Chan, Hong Kong</i>
9:10 to 9:30 AM	<b>Hepatitis B Reactivation During Immunosuppressive Therapy</b> <i>Joel Chua, Baltimore</i>
9:30 to 9:50 AM	<b>The Use of HCC Risk Assessment Scoring Systems in CHB</b> <i>Arlin King Go, Manila</i>
9:50 to 10:00 AM	<b>Discussion/Question &amp; Answer</b>

## Hepatic Tumors

Meeting Room 2, 8:30 to 10:00 AM

Chairs: Wendell Espinosa (Bacolod), Tawesak Tanwandee (Bangkok)

8:30 to 8:50 AM	<b>Combined Hepatocellular-Cholangiocarcinoma: Diagnosis and Management</b> <i>Sang Hoon Ahn, Seoul</i>
8:50 to 9:10 AM	<b>Differentiating HCC from non-HCC malignant tumors of the Liver Using LIRADS</b> <i>Cher Heng Tan, Singapore</i>
9:10 to 9:30 AM	<b>Intrahepatic Cholangiocarcinoma: Controversies and Challenges</b> <i>Jenny Limquiaco, Cebu</i>
9:30 to 9:50 AM	<b>Liver Transplantation for Hilar Cholangiocarcinoma</b> <i>Robert Gish, San Diego</i>
9:50 to 10:00 AM	<b>Discussion/Question &amp; Answer</b>

# Morning Parallel Symposia

## Liver Failure

Meeting Room 3, 8:30 to 10:00 AM

Chair: A Kadir Dökmeci (Ankara)

8:30 to 8:50 AM	<b>Acute Liver Failure from DILI: Evolving Etiologies</b> <i>Wasim Jafri, Karachi</i>
8:50 to 9:10 AM	<b>Stem Cell Therapy for Acute on Chronic Liver Failure: Current Evidence and Applications</b> <i>Fu Sheng Wang, Beijing</i>
9:10 to 9:30 AM	<b>Liver Failure from Severe Alcoholic Hepatitis: Emerging Medical Therapies and Remaining Challenges in Transplantation</b> <i>Robert Brown, New York</i>
9:30 to 9:50 AM	<b>Evidence for Albumin Use in Organ Failure and For Immunomodulation in ACLF</b> <i>Ashok Choudhury, New Delhi</i>
9:50 to 10:00 AM	<b>Discussion/Question &amp; Answer</b>

## General Hepatology

Meeting Room 4, 8:30 to 10:00 AM

Chairs: Jaime Ignacio (Manila), Barjesh Sharma (New Delhi)

8:30 to 8:50 AM	<b>Pain Management in Patients with Cirrhosis</b> <i>Rino Gani, Jakarta</i>
8:50 to 9:10 AM	<b>Evaluation of a Patient with Abnormal Liver Tests</b> <i>Juliet Cervantes, Manila</i>
9:10 to 9:30 AM	<b>Assessment of Preoperative Risk in Cirrhotic Patients</b> <i>Jade Jamias, Manila</i>
9:30 to 9:50 AM	<b>Updates on the Management of Hepatic Encephalopathy</b> <i>Barjesh Sharma, New Delhi</i>
9:50 to 10:00 AM	<b>Discussion/Question &amp; Answer</b>



# Morning Parallel Symposia

## NAFLD I

Meeting Room 5, 8:30 to 10:00 AM

Chairs: Ramon Carpio (Manila), Claudio Tiribelli (Trieste)

8:30 to 8:50 AM	<b>Current Understanding in the Pathophysiology and Natural History of NAFLD</b> <i>Henning Gronbaek, Aarhus</i>
8:50 to 9:10 AM	<b>Extracellular Vesicles in NAFLD</b> <i>Gyongyi Szabo, Amherst</i>
9:10 to 9:30 AM	<b>Models for Studying NAFLD and NASH</b> <i>Claudio Tiribelli, Trieste</i>
9:30 to 9:50 AM	<b>Current Applications of Endoscopic and Surgical Options in NAFLD</b> <i>Sombat Treeprasertsuk, Bangkok</i>
9:50 to 10:00 AM	<b>Discussion/Question &amp; Answer</b>

# Morning Parallel Symposia

## Multidisciplinary Management of Liver Dominant Colorectal Metastases

Meeting Room 6, 8:30 to 10:00 AM

Chairs: Eternity Labio (Manila), Ronnie Poon (Hong Kong)

8:30 to 8:50 AM	<b>Role of the Hepatologist</b> <i>Masatoshi Kudo, Osaka</i>
8:50 to 9:10 AM	<b>Role of the Surgeon</b> <i>Ronnie Poon, Hong Kong</i>
9:10 to 9:30 AM	<b>Role of the Interventional Radiologist</b> <i>Ramon Santos-Ocampo, Manila</i>
9:30 to 9:50 AM	<b>Role of the Medical Oncologist</b> <i>Stephen Lam Chan, Hong Kong</i>
9:50 to 10:00 AM	<b>Discussion/Question &amp; Answer</b>

## Hepatobiliary Surgery

Meeting Room 7, 8:30 to 10:00 AM

Chairs: Vanessa De Villa (Manila), Chung-Mau Lo (Hong Kong)

8:30 to 8:50 AM	<b>Scaling the ALPPS - A strategy to Improve Resectability of Malignant Tumors</b> <i>Chung-Mau Lo, Hong Kong</i>
8:50 to 9:10 AM	<b>Minimal Access Liver Surgery: Laparoscopic versus Robotic Hepatectomy</b> <i>Ki-Hun Kim, Seoul</i>
9:10 to 9:30 AM	<b>Hepatectomy for Recurrent HCC: Safety and Outcomes</b> <i>Pierce Chow, Singapore</i>
9:30 to 9:50 AM	<b>Liver Resection in the Patient with Chronic Liver Disease</b>
9:50 to 10:00 AM	<b>Discussion/Question &amp; Answer</b>

# Afternoon Parallel Symposia

## APASL-AASLD Symposium on Hepatocellular Carcinoma

Reception Hall, 2:30 to 5:50 PM

Chairs: Judy Lao-Tan (Cebu), Michael Fried (Chapel Hill)

2:30 to 2:50 PM	<b>Early Stage HCC: Resection versus Liver Transplantation?</b> <i>Ronnie Poon, Hong Kong</i>
2:50 to 3:10 PM	<b>DAA's and HCC Recurrence After Curative Therapy: Is the Jury Out?</b> <i>Fasiha Kanwal, Dallas</i>
3:10 to 3:30 PM	<b>Treatment of Hepatocellular Carcinoma in Patients Awaiting Liver Transplantation</b> <i>Paul Thuluvath, Baltimore</i>
3:30 to 3:50 PM	<b>Combined Transarterial Chemoembolization and Sorafenib in Intermediate Stage HCC</b> <i>Rajender Reddy, Philadelphia</i>
3:50 to 4:00 PM	<b>Discussion/Question &amp; Answer</b>

Chairs: Jenny Limquiaco (Cebu), Ray Kim (Palo Alto)

4:20 to 4:40 PM	<b>Current Concepts in TACE Refractory HCC and Treatment Options</b> <i>Robert Gish, San Diego</i>
4:40 to 5:00 PM	<b>Role of Selective Internal Radiation Therapy in Locally Advanced HCC</b> <i>Pierce Chow, Singapore</i>
5:00 to 5:20 PM	<b>Role of Radiation Therapy in HCC</b> <i>Jinsil Seong, Seoul</i>
5:20 to 5:40 PM	<b>Systemic Therapies in HCC: Choosing the Right Drug for the Right Patient</b> <i>Stephen Lam Chan, Hong Kong</i>
5:40 to 5:50 PM	<b>Discussion/Question &amp; Answer</b>

# Afternoon Parallel Symposia

## Pediatric Hepatology: Spotlight on NAFLD in Children

Meeting Room 4, 2:30 to 5:50 PM

Chair: Jorge Bezerra (Cincinnati)

2:30 to 2:50 PM	<b>Epidemiology of NAFLD in children in the Asia-Pacific Region</b> <i>Germana Gregorio, Manila</i>
2:50 to 3:10 PM	<b>Genetic and Epigenetic Determinants of NAFLD in Children</b> <i>Aabha Nagral, Mumbai</i>
3:10 to 3:30 PM	<b>Natural History and Prognosis of NAFLD in Children</b> <i>Marion Aw, Singapore</i>
3:30 to 3:50 PM	<b>Pathogenesis of NAFLD in children: The Multiorgan Crosstalk</b> <i>Jorge Bezerra, Cincinnati</i>
3:50 to 4:00 PM	<b>Discussion/Question &amp; Answer</b>

Chairs: Maribel Vitug-Sales (Manila), Marion Aw (Singapore)

4:20 to 4:40 PM	<b>Screening and Diagnosis of NAFLD in children: Why, Who, and with What?</b> <i>TBA</i>
4:40 to 5:00 PM	<b>NAFLD as a Systemic Disease in Children and The Multisystemic Approach to Evaluation and Treatment</b> <i>Lin Yu-Cheng, Taipei</i>
5:00 to 5:20 PM	<b>Histopathology of NAFLD in Children: Is it Different from Adults?</b> <i>Juan Putra, Toronto</i>
5:20 to 5:40 PM	<b>Management of Children with NAFLD</b> <i>Seema Alam, New Delhi</i>
5:40 to 5:50 PM	<b>Discussion/Question &amp; Answer</b>

# Afternoon Parallel Symposia

## Inherited and Metabolic Liver Diseases

Meeting Room 2, 2:30 to 4:00 PM

Chairs: Jade Jamias (Manila), Maryam Moini (Shiraz)

2:30 to 2:50 PM	<b>Updates on Wilson Disease</b> <i>Maryam Moini, Shiraz</i>
2:50 to 3:10 PM	<b>Approach to the Patient with Iron Overload</b> <i>Darrell Crawford, Brisbane</i>
3:10 to 3:30 PM	<b>Adults with Inherited Liver Diseases other than HHC or Wilson Disease</b> <i>Geoffrey McCaughan, Sydney</i>
3:30 to 3:50 PM	<b>The Role of Liver Biopsy in Metabolic Liver Diseases</b> <i>Juan Putra, Toronto</i>
3:50 to 4:00 PM	<b>Discussion/Question &amp; Answer</b>

## Hepatitis C I

Meeting Room 5, 2:30 to 4:00 PM

Chairs: Evelyn Dy (Manila), Rakesh Aggarwal (Lucknow)

2:30 to 2:50 PM	<b>Sofosbuvir-based Therapies in Patients with Chronic Kidney Disease</b> <i>Ajay Duseja, Chandigarh</i>
2:50 to 3:10 PM	<b>Extrahepatic Manifestations of Chronic Hepatitis C: The Role of DAAs</b> <i>Rosmawati Mohamed, Kuala Lumpur</i>
3:10 to 3:30 PM	<b>HCC Incidence and Recurrence after DAAs: New Insights</b> <i>Necati Ormeci, Ankara</i>
3:30 to 3:50 PM	<b>Treatment of Decompensated Cirrhosis in the Patient on the Transplant Wait List</b> <i>Simone Strasser, Sydney</i>
3:50 to 4:00 PM	<b>Discussion/Question &amp; Answer</b>

# Afternoon Parallel Symposia

## Tuberculosis and the Liver

Meeting Room 3, 2:30 to 4:00 PM

Chairs: Cybele Abad (Manila), Wasim Jafri (Karachi)

2:30 to 2:50 PM	<b>Hepatobiliary Tuberculosis: Diagnosis and Management</b> <i>TBA</i>
2:50 to 3:10 PM	<b>Management of Hepatic Adverse Drug Reactions Due to Anti-TB Drugs</b> <i>TBA</i>
3:10 to 3:30 PM	<b>End Stage Biliary Cirrhosis from Hepatobiliary TB: From Stents to Transplant</b> <i>Manoj Kumar Sharma, New Delhi</i>
3:30 to 3:50 PM	<b>Management of TB in the Peritransplant Setting: Donor and Recipient</b> <i>Jack Bruminhent, Bangkok</i>
3:50 to 4:00 PM	<b>Discussion/Question &amp; Answer</b>

# Afternoon Parallel Symposia

## Viral Hepatitis in Organ Transplantation

Meeting Room 1, 4:20 to 5:50 PM

Chairs: Janus Ong (Manila), Alexander Thompson (Melbourne)

4:20 to 4:40 PM	<b>HCV in LT Candidates: Treat Before or After Transplantation?</b> <i>Leon Adams, Perth</i>
4:40 to 5:00 PM	<b>Prevention of Hepatitis B Recurrence after LT in 2019</b> <i>Ed Gane, Auckland</i>
5:00 to 5:20 PM	<b>Should We Use Anti-HBc Positive Donors in Kidney transplantation?</b> <i>TBA</i>
5:20 to 5:40 PM	<b>Viral Hepatitis in Solid Organ Transplantation Other Than The Liver</b> <i>Alexander Thompson, Melbourne</i>
5:40 to 5:50 PM	<b>Discussion/Question &amp; Answer</b>

## Liver Support Systems

Meeting Room 3, 4:20 to 5:50 PM

Chairs: Edhel Tripon (Manila), Paolo Angeli (Padova)

4:20 to 4:40 PM	<b>Bioartificial Liver Support: Ready for Play?</b> <i>Virendra Singh, Chandigarh</i>
4:40 to 5:00 PM	<b>Therapeutic Plasma Exchange for Liver Failure: Protocols and Outcomes</b> <i>Qin Ning, Shanghai</i>
5:00 to 5:20 PM	<b>Extracorporeal Liver Support Systems: Review of Current and Future Tools</b> <i>Paolo Angeli, Padova</i>
5:20 to 5:40 PM	<b>Practical Tips in Use of Extracorporeal Liver Support Systems in the ICU: Patient Selection, Plasma Exchange or Plasma Perfusion</b> <i>Manoj Kumar Sharma, New Delhi</i>
5:40 to 5:50 PM	<b>Discussion/Question &amp; Answer</b>

# Afternoon Parallel Symposia

## Cholestatic and Autoimmune Liver Diseases

Meeting Room 2, 4:20 to 5:50 PM

Chairs: Marilyn Arguillas (Davao), Jinlin Hou (Guangzhou)

4:20 to 4:40 PM	<b>Overlap Syndromes: Recognition and Management</b> <i>Atsushi Tanaka, Tokyo</i>
4:40 to 5:00 PM	<b>Primary Biliary Cirrhosis: Beyond Ursodeoxycholic Acid</b> <i>Tom Karlsen, Oslo</i>
5:00 to 5:20 PM	<b>Treatment of Steroid-Refractory Autoimmune Hepatitis</b> <i>Ji Dong Jia, Beijing</i>
5:20 to 5:40 PM	<b>Cessation of Immunosuppression in Patients with Autoimmune Hepatitis in Clinical Remission</b> <i>Atsushi Tanaka, Tokyo</i>
5:40 to 5:50 PM	<b>Discussion/Question &amp; Answer</b>



# State of the Art Lectures

Meeting Room 1, 2:30 to 4:00 PM

---

2:30 to 3:00 PM	<b>Hepatocellular Carcinoma in the Era of DAAs</b> <i>Masao Omata, Tokyo</i> <i>Chair: Jose Sollano, Manila</i>
3:00 to 3:30 PM	<b>Modulation of Gut Microbiome in Liver Disease</b> <i>Jasmohan Bajaj, Richmond</i> <i>Chair: Marichona Naval, Manila</i>
3:30 to 4:00 PM	<b>Regression of Liver Cirrhosis: A Paradigm Shift</b> <i>Detlef Schuppan, Mainz</i> <i>Chair: Stephen Wong, Manila</i>

---

Meeting Room 5, 4:20 to 5:30 PM

---

4:20 to 4:50 PM	<b>Beta-Blockers: Their Role in Portal Hypertension in 2019</b> <i>Guadalupe Garcia-Tsao, New Haven</i> <i>Chair: Marceliano Aquino, Manila</i>
5:00 to 5:30 PM	<b>The Global Burden of Nash</b> <i>Zobair Younossi, Fairfax</i> <i>Chair: Felix Zaño, Manila</i>

---



# 23 February

## Saturday

# Morning Parallel Symposia

## Hepatitis B II

Meeting Room 1, 8:00 to 9:30 AM

Chair: Therese Macatula (Manila), Ji Dong Jia (Beijing)

8:00 to 8:20 AM	<b>The Role of Pegylated Interferon in the Treatment of Chronic Hepatitis B in 2019</b> <i>Qin Ning, Shanghai</i>
8:20 to 8:40 AM	<b>Long-Term Safety and Efficacy of Nucleoside Analogues</b> <i>Ed Gane, Auckland</i>
8:40 to 9:00 AM	<b>Novel Biomarkers for Hepatitis B</b> <i>Henry Chan, Hong Kong</i>
9:00 to 9:20 AM	<b>Stopping Antiviral Therapy in Chronic Hepatitis B: Practical Guide</b> <i>Ji Dong Jia, Beijing</i>
9:20 to 9:30 AM	<b>Discussion/Question &amp; Answer</b>

## Hepatitis C II

Meeting Room 5, 8:00 to 9:30 AM

Chairs: Jose Tan (Manila), David Muljono (Jakarta)

8:00 to 8:20 AM	<b>Is There Still a Role for Genotyping in the Era of Pangenotypic DAAs?</b> <i>Joel Chua, Baltimore</i>
8:20 to 8:40 AM	<b>Drug-Drug Interactions in HCV Treatment: Practical Guide</b> <i>Alexander Thompson, Melbourne</i>
8:40 to 9:00 AM	<b>Reactivation of Hepatitis B in HCV treatment</b> <i>Jia-Horng Kao, Taipei</i>
9:00 to 9:20 AM	<b>Resistance Testing: Application in Current HCV Treatment Practices</b> <i>Lai Wei, Beijing</i>
9:20 to 9:30 AM	<b>Discussion/Question &amp; Answer</b>

# Morning Parallel Symposia

## NAFLD II

Meeting Room 4, 8:00 to 9:30 AM

Chairs: Angelo Lozada (Manila), Wah-Keong Chan (Kuala Lumpur)

8:00 to 8:20 AM	<b>Clinical Development of New Drugs for NAFLD: What Can We Learn from Basic Models</b> <i>Frank Tacke, Aachen</i>
8:20 to 8:40 AM	<b>The Gut Microbiome in NAFLD</b> <i>Tom Karlsen, Oslo</i>
8:40 to 9:00 AM	<b>How Do You Treat Non-obese or Lean NAFLD?</b> <i>Jian Gao Fan, Shanghai</i>
9:00 to 9:20 AM	<b>Moderate Alcohol Use in NAFLD: Good or Bad?</b> <i>Wah Keong Chan, Kuala Lumpur</i>
9:20 to 9:30 AM	<b>Discussion/Question &amp; Answer</b>

## Coagulation Disorders

Meeting Room 2, 8:30 to 10:00 AM

Chairs: Felix Zaño (Manila), Rakhi Maiwall (New Delhi)

8:30 to 8:50 AM	<b>Risk Assessment in Coagulopathic Cirrhotic Patients Undergoing Surgery</b> <i>Tawasek Tanwandee, Bangkok</i>
8:50 to 9:10 AM	<b>Use of Anticoagulants and Antiplatelets in Cirrhotic Patients</b> <i>Edhel Tripon, Manila</i>
9:10 to 9:30 AM	<b>Rationale Use of Blood Products in the Cirrhotic Patient</b> <i>Didier Samuel, VilleJeuF</i>
9:30 to 9:50 AM	<b>Anticoagulation in Portal Vein Thrombosis in Cirrhotics</b> <i>Rakhi Maiwall, New Delhi</i>
9:50 to 10:00 AM	<b>Discussion/Question &amp; Answer</b>

# Morning Parallel Symposia

## Cirrhosis and Its Complications I

Meeting Room 3, 8:30 to 10:00 AM

Chairs: Frederick Dy (Manila), Hasmik Ghazinian (Yerevan)

8:30 to 8:50 AM	<b>Monitoring Cirrhosis Regression: Biopsy versus Non-invasive Methods</b> <i>Angela Salvaña, Manila</i>
8:50 to 9:10 AM	<b>Non-invasive Evaluation of Portal Hypertension: Current and Emerging Tools</b> <i>Han-Chieh Lin, Taipei</i>
9:10 to 9:30 AM	<b>New Perspectives on the Diagnosis and Management of Acute Kidney Injury in Hepatorenal Syndrome</b> <i>James Fung, Singapore</i>
9:30 to 9:50 AM	<b>Bone Disease in Chronic Liver Disease</b> <i>Eternity Labio, Manila</i>
9:50 to 10:00 AM	<b>Discussion/Question &amp; Answer</b>

## Non-Invasive Testing in Liver Disease

Meeting Rooms 7 & 8, 8:30 to 10:00 AM

Chairs: Ernesto Olympia (Manila), Keith Chiu (Hong Kong)

8:30 to 8:50 AM	<b>Serum Biomarkers in Fibrosis Staging and Monitoring</b> <i>TBA</i>
8:50 to 9:10 AM	<b>Ultrasound-based Elastography in Assessing Fibrosis</b> <i>Grace Wong, Hong Kong</i>
9:10 to 9:30 AM	<b>MRI in the Evaluation of Liver Disease and Fibrosis</b> <i>Keith Chiu, Hong Kong</i>
9:30 to 9:50 AM	<b>The Use of Non-Invasive Testing in Assessing Severity of Cirrhosis and Survival</b> <i>Piratvisuth Teerha, Hat-yai</i>
9:50 to 10:00 AM	<b>Discussion/Question &amp; Answer</b>

# Morning Parallel Symposia

## Drug Discovery

Meeting Room 6, 8:30 to 10:00 AM

Chair: Ian Homer Cua (Manila)

8:30 to 8:50 AM	<b>Reversal of NASH Fibrosis with Pharmacotherapy</b> <i>Paul Thuluvath, Baltimore</i>
8:50 to 9:10 AM	<b>New Drug Targets in Hepatitis B</b> <i>Man-Fung Yuen, Hong Kong</i>
9:10 to 9:30 AM	<b>Is There a Role for Statins in Liver Cirrhosis?</b> <i>Ian Homer Cua, Manila</i>
9:30 to 9:50 AM	<b>Alcoholic Hepatitis: Beyond Corticosteroids</b> <i>Gyongyi Szabo, Amherst</i>
9:50 to 10:00 AM	<b>Discussion/Question &amp; Answer</b>

## APASL-ALEH Symposium: Tropical Liver Disease

Reception Hall, 8:30 to 10:00 AM

Chair: Suzane Ono-nita (Sao Paolo)

8:30 to 8:50 AM	<b>Hepatic Schistosomiasis: Diagnosis and Management</b> <i>Raymundo Parana, Salvador</i>
8:50 to 9:10 AM	<b>Helminth Infections and the Liver</b> <i>Wendell Espinosa, Bacolod</i>
9:10 to 9:30 AM	<b>Chronic Hepatitis E Infection: Clinical Aspects and Treatment Approaches</b> <i>TBA</i>
9:30 to 9:50 AM	<b>Patterns of Liver Involvement in Febrile Icteric Illnesses (Malaria, Leptospirosis, Dengue): Incidence and Clinical Presentation</b> <i>Khin Maung Win, Yangon</i>
9:50 to 10:00 AM	<b>Discussion/Question &amp; Answer</b>

# Afternoon Parallel Symposia

## APASL-EASL Symposium on Alcoholic Liver Disease

Reception Hall, 2:00 to 5:20 PM

### Session 1: Alcohol as a Leading Liver Disease

Chairs: Roberto De Guzman, Jr (Manila), Didier Samuel (VilleJeuF)

2:00 to 2:20 PM	<b>Diagnosis of alcoholic liver disease: current concepts and new developments</b> <i>Rino Gani, Jakarta</i>
2:20 to 2:40 PM	<b>Identification and Management of Alcohol Dependence and Withdrawal in Alcoholic Liver Disease</b> <i>Darrell Crawford, Brisbane</i>
2:40 to 3:00 PM	<b>Malnutrition and Obesity in Alcoholic Liver Disease</b> <i>Diana Payawal, Manila</i>
3:00 to 3:20 PM	<b>The EASL Guidelines on Alcoholic Liver Disease</b> <i>Franck Tacke, Aachen</i>
3:20 to 3:30 PM	<b>Discussion/Question &amp; Answer</b>

### Session 2: Managing Critical Cases of Alcoholic Liver Disease

Chairs: Angela Salvaña (Manila), Frank Tacke (Aachen)

3:50 to 4:15 PM	<b>Debate: Steroids for Alcoholic Hepatitis?</b> <i>Ashok Choudhury, New Delhi</i> <i>Philippe Mathurin, Paris</i>
4:15 to 4:35 PM	<b>Liver Transplantation for Severe Alcoholic Hepatitis</b> <i>Francois Durand, Clichy</i>
4:35 to 4:55 PM	<b>Critical Care Medicine Management for Decompensated Alcoholic Cirrhosis</b> <i>Didier Samuel, VilleJeuF</i>
4:55 to 5:20 PM	<b>Case Discussion: Panel</b>

# Afternoon Parallel Symposia

## Hepatocellular Carcinoma I

Meeting Room 1, 2:00 to 5:20 PM

### Systemic Therapies

Chairs: Judith Gapasin Tongco (Manila), Sang Hoon Ahn (Seoul)

2:00 to 2:20 PM	<b>Approved First Line Systemic Therapies: How I Use Them</b> <i>Kwang Hyub Han, Seoul</i>
2:20 to 2:40 PM	<b>Approved Second Line Systemic Therapies: How I Use Them</b> <i>Stephen Lam Chan, Hong Kong</i>
2:40 to 3:00 PM	<b>Ongoing Trials in Systemic Therapies for HCC</b> <i>Masatoshi Kudo, Tokyo</i>
3:00 to 3:20 PM	<b>Checkpoint Inhibitors and Liver Injury: Approach and Management</b> <i>Sang Hoon Ahn, Seoul</i>
3:20 to 3:30 PM	<b>Discussion/Question &amp; Answer</b>

### Treatment of Intermediate Stage HCC: From Surgery to Systemic Therapy

Chairs: Lawrence Liu (Cebu), Han-Chieh Lin (Taipei)

3:50 to 4:10 PM	<b>Surgery (Including Liver Transplantation)</b> <i>Johnny Hong, Milwaukee</i>
4:10 to 4:30 PM	<b>Intraarterial Therapy</b> <i>Ramon Santos-Ocampo, Manila</i>
4:30 to 4:50 PM	<b>Radiation Therapy</b> <i>Jinsil Seong, Seoul</i>
4:50 to 5:10 PM	<b>Systemic Therapy</b> <i>Han-Chieh Lin, Taipei</i>
5:10 to 5:20 PM	<b>Case Discussion: Panel</b>



# Afternoon Parallel Symposia

## Liver Pathology

Meeting Room 2, 2:00 to 3:30 PM

Chairs: Leticia Guzman (Manila), Rouche Dela Cruz (Manila)

2:00 to 2:20 PM	<b>Drug-induced Liver Injury: Should Liver Biopsies Be Routinely Performed?</b> <i>Isabel Fiel, New York</i>
2:20 to 2:40 PM	<b>Cryptogenic Cirrhosis: An Approach to Diagnosis in the Era of Molecular Pathology</b> <i>Jose Jasper Andal, Manila</i>
2:40 to 3:00 PM	<b>Diagnosis of Hepatocellular Neoplasms: The Role of immunohistochemical Staining and Genomic Testing in a Resource-challenged Setting</b> <i>Rouche Dela Cruz, Manila</i>
3:00 to 3:20 PM	<b>Liquid Biopsy in Liver Diseases</b> <i>Isabel Fiel, New York</i>
3:20 to 3:30 PM	<b>Discussion/Question &amp; Answer</b>

## NAFLD III

Meeting Room 4, 2:00 to 3:30 PM

Chairs: Melchor Chan (Manila), Teerha Piratvisuth (Hat-yai)

2:00 to 2:20 PM	<b>Clinical and Economic Burden of NAFLD in Asia-Pacific</b> <i>Teerha Piratvisuth, Hat-yai</i>
2:20 to 2:40 PM	<b>Predicting Risk of Liver-related Morbidity and Mortality in NAFLD: is Fibrosis the Key?</b> <i>Vlad Ratziu, Paris</i>
2:40 to 3:00 PM	<b>NAFLD and Cardiovascular Morbidity</b> <i>Jian Gao Fan, Shanghai</i>
3:00 to 3:20 PM	<b>Liver Transplantation for NAFLD</b> <i>Robert Brown, New York</i>
3:20 to 3:30 PM	<b>Discussion/Question &amp; Answer</b>

# Afternoon Parallel Symposia

## APASL-Internal Ascites Club Symposium

Meeting Room 3, 2:00 to 3:30 PM

Chair: Francois Durand (Clichy)

2:00 to 2:20 PM	<b>New Insights on the Use of Albumin in Cirrhosis with Ascites</b> <i>Paolo Angeli, Padova</i>
2:20 to 2:40 PM	<b>Mechanisms Involved in Bacterial Translocation in Patients with Cirrhosis</b> <i>Florence Wong, Toronto</i>
2:40 to 3:00 PM	<b>Refractory Ascites in Cirrhosis: Indwelling Catheters, TIPS, Paracentesis, or Transplantation?</b> <i>Francois Durand, Clichy</i>
3:00 to 3:20 PM	<b>When and How to Treat Hyponatremia in Patients with Cirrhosis and Ascites?</b> <i>Rakhi Maiwall, New Delhi</i>
3:20 to 3:30 PM	<b>Discussion/Question &amp; Answer</b>

# Afternoon Parallel Symposia

## Cirrhosis and Its Complications II

Meeting Room 3, 3:50 to 5:20 PM

Chair: Jonathan Sandejas (Manila)

3:50 to 4:10 PM	<b>Clinical Applications of TIPS in Portal Hypertension</b> <i>Guadalupe Garcia-Tsao, New Haven</i>
4:10 to 4:30 PM	<b>Current Strategies and New Insights on the Treatment of Bleeding Esophageal Varices</b> <i>TBA</i>
4:30 to 4:50 PM	<b>Pulmonary and Cardiac Complications of Cirrhosis</b> <i>Cosmas Lesmana, Jakarta</i>
4:50 to 5:10 PM	<b>Management of Minimal Hepatic Encephalopathy</b> <i>Yogesh Chawla, Chandigarh</i>
5:10 to 5:20 PM	<b>Discussion/Question &amp; Answer</b>

## Diagnostic Radiology in Liver Disease

Meeting Room 2, 3:50 to 5:20 PM

Chairs: Joseph Bocobo (Manila), Cher Heng Tan (Singapore)

3:50 to 4:10 PM	<b>LIRADS: A Guide for the Clinician</b> <i>Keith Chiu, Hong Kong</i>
4:10 to 4:30 PM	<b>Review of Hepatobiliary Contrast Agents: Clinical Applications and Challenges</b> <i>James Delos Santos, Manila</i>
4:30 to 4:50 PM	<b>The Role of PET-CT in Hepatobiliary Malignancies</b> <i>Allan Manalaysay, Manila</i>
4:50 to 5:10 PM	<b>The Use of MRI in the Imaging of Liver Tumors</b> <i>Cher Heng Tan, Singapore</i>
5:10 to 5:20 PM	<b>Discussion/Question &amp; Answer</b>

# Afternoon Parallel Symposia

## Nutrition in Liver Disease

Meeting Room 4, 3:50 to 5:20 PM

Chairs: Oscar Cabahug (Manila), Gyongyi Szabo (Amherst)

3:50 to 4:10 PM	<b>The Role of Micronutrient Supplementation in the Cirrhotic Patient</b> <i>TBA</i>
4:10 to 4:30 PM	<b>Outpatient Nutritional Management of the Cirrhotic Patient</b> <i>Osamu Yokusuka, Chiba</i>
4:30 to 4:50 PM	<b>Assessment and Management of Sarcopenic Obesity in NAFLD</b> <i>Gyongyi Szabo, Amherst</i>
4:50 to 5:10 PM	<b>Nutrition in the Critically-Ill Cirrhotic Patient</b> <i>Marilyn Arguillas, Davao</i>
5:10 to 5:20 PM	<b>Discussion/Question &amp; Answer</b>

## Viral Hepatitis

Meeting Room 5, 3:50 to 5:20 PM

Chair: John Arnel Pangilinan (Manila)

3:50 to 4:10 PM	<b>Elimination of Hepatitis B cccDNA: Dream or Reality</b> <i>George Lau, Beijing</i>
4:10 to 4:30 PM	<b>The Use of HBsAg Quantification in the Natural History and Treatment of Chronic Hepatitis B</b> <i>Man-Fung Yuen, Hong Kong</i>
4:30 to 4:50 PM	<b>Viral Hepatitis and Pregnancy</b> <i>Wei Lai, Beijing</i>
4:50 to 5:10 PM	<b>Impact of Hepatic Steatosis on Viral Hepatitis</b> <i>Wah Kheong Chan, Kuala Lumpur</i>
5:10 to 5:20 PM	<b>Discussion/Question &amp; Answer</b>

# State of the Art Lectures

## Reception Hall

---

9:30 to 10:00 AM **Current Status of Immunotherapy in HCC**

*Chiun Hsu*

*Chair: Jade Jamias, Manila*

---

1:30 to 2:00 PM **Right versus Left Lobe Adult LDLT: Is the Debate Over?**

*Chung-Mau Lo, Hong Kong*

*Chair: Vanessa De Villa, Manila*

---

## Meeting Room 5

---

2:00 to 2:30 PM **Current and Future Therapeutic Approaches for ACLF**

*Shiv Sarin, New Delhi*

*Chair: Erlinda Valdellon, Manila*

---

3:00 to 3:30 PM **Precision Medicine in HCC**

*TBA*

*Chair: Ian Homer Cua, Manila*

---

## Meeting Room 1

---

9:30 to 10:00 AM **Access to DAAs: Perspectives from Asia**

*George Lau, Beijing*

*Chair: Diana Payawal, Manila*

---

## Meeting Room 1

---

1:30 to 2:00 PM **Elimination of Hepatitis B in Asia Pacific: Is This Possible?**

*Jose Sollano, Manila*

*Chair: Rosmawati Mohamed, Kuala Lumpur*

---

## Meeting Room 4

---

9:30 to 10:00 AM **Treatment Advances in NAFLD**

*Vincent Wong, Hong Kong*

*Chair: Judy Lao-Tan, Cebu*

---



# 24 February

## Sunday

# Morning Parallel Symposia

## Hepatocellular Carcinoma II

Meeting Room 2, 8:00 to 9:30 AM

### Ablative Techniques in Early HCC

Chairs: Arlin King Go (Manila), Wasim Jafri (Karachi)

8:30 to 8:50 AM	<b>Percutaneous Ablation in Early Hepatocellular Carcinoma: Current Status in Asia-Pacific</b> <i>Shuichiro Shiina, Tokyo</i>
8:50 to 9:10 AM	<b>Radiofrequency Ablation: When and How I Do It</b> <i>Shi Ming Lin, Taipei</i>
9:10 to 9:30 AM	<b>Microwave Ablation: When and How I Do It</b> <i>Kai-Wen Huang, Taipei</i>
9:30 to 9:50 AM	<b>Irreversible Electroporation: When and How I Do It</b> <i>Kai-Wen Huang, Taipei</i>
9:50 to 10:00 AM	<b>Discussion/Question &amp; Answer</b>

## Drug and Toxin-induced Liver Injury

Meeting Room 3, 8:00 to 9:30 AM

Chairs: Angelo Lozada (Manila), Dong-Jin Suh (Asan)

8:30 to 8:50 AM	<b>Herbal Medicine and Health Supplement Use in CLD: Guides and Precautions</b> <i>Judy Lao-Tan, Cebu</i>
8:50 to 9:10 AM	<b>Assessment and Management of Chemotherapy-Induced Liver Injury</b> <i>Shahab Abid, Karachi</i>
9:10 to 9:30 AM	<b>Biomarkers in DILI: New Aids in Diagnosis and Prognosis</b> <i>Raymundo Parana, Salvador</i>
9:30 to 9:50 AM	<b>Hepatoprotectants in DILI: What is the Evidence?</b> <i>David Muljono, Jakarta</i>
9:50 to 10:00 AM	<b>Discussion/Question &amp; Answer</b>

# Morning Parallel Symposia

## HIV and the Liver

Meeting Room 3, 10:20 to 11:50 AM

Chairs: Marvin Basco (Manila), Cosmas Lesmana (Jakarta)

---

10:20 to 10:40 AM **Epidemiology, Diagnosis, and Management of HCC in HIV-Infected Patients**

*Cosmas Lesmana, Jakarta*

---

10:40 to 11:00 AM **NAFLD/NASH in Patients with HIV**

*Ira Yu, Manila*

---

11:00 to 11:20 AM **Management of HIV Patients Co-infected with HBV/HCV**

*Edsel Salvaña, Manila*

---

11:20 to 11:40 AM **Management of Cirrhosis in Persons Living with HIV**

*Tawasek Tanwandee, Bangkok*

---

11:40 to 11:50 AM **Discussion/Question & Answer**

---